NASDAQ:CVAC - Nasdaq - NL0015436031 - Common Stock - Currency: USD
NASDAQ:CVAC (5/23/2025, 3:48:56 PM)
4.115
-0.04 (-1.08%)
The current stock price of CVAC is 4.115 USD. In the past month the price increased by 27.61%. In the past year, price increased by 12.74%.
Symbol | Company Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
ABBV | ABBVIE INC | 17.9 | 325.15B | ||
AMGN | AMGEN INC | 13.12 | 146.41B | ||
GILD | GILEAD SCIENCES INC | 13.91 | 134.00B | ||
VRTX | VERTEX PHARMACEUTICALS INC | N/A | 111.96B | ||
REGN | REGENERON PHARMACEUTICALS | 13.3 | 63.62B | ||
ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 37.65B | ||
ARGX | ARGENX SE - ADR | 100.15 | 35.90B | ||
ONC | BEIGENE LTD-ADR | 6 | 26.02B | ||
BNTX | BIONTECH SE-ADR | N/A | 23.71B | ||
NTRA | NATERA INC | N/A | 20.91B | ||
SMMT | SUMMIT THERAPEUTICS INC | N/A | 19.24B | ||
BIIB | BIOGEN INC | 7.97 | 18.47B |
CureVac BV is a clinical-stage biopharmaceutical company, which engages in developing transformative medicines based on messenger ribonucleic acid (mRNA). The company is headquartered in Tuebingen, Baden-Wuerttemberg and currently employs 825 full-time employees. The company went IPO on 2020-08-14. The firm develops transformative medicines based on messenger ribonucleic acid, or mRNA. The firm's mRNAs are designed to prevent infections and to treat diseases by mimicking human biology to synthesize the desired proteins. Its technology platform optimizes mRNA constructs that encode functional proteins which either induce a desired immune response or replace defective or missing proteins using the cell’s intrinsic translation machinery. The firm's product portfolio includes clinical and preclinical candidates across multiple disease indications in prophylactic vaccines, oncology, and molecular therapy. In prophylactic vaccines, the Company is advancing its second-generation mRNA backbone against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and a range of infectious diseases, including seasonal influenza, in collaboration with GSK(Glaxo Smith Kline).
CUREVAC NV
Friedrich-Miescher-Str. 15
Tuebingen BADEN-WUERTTEMBERG 72076 DE
CEO: Franz-Werner Haas
Employees: 904
Phone: 49707198830
The current stock price of CVAC is 4.115 USD. The price decreased by -1.08% in the last trading session.
The exchange symbol of CUREVAC NV is CVAC and it is listed on the Nasdaq exchange.
CVAC stock is listed on the Nasdaq exchange.
13 analysts have analysed CVAC and the average price target is 6.32 USD. This implies a price increase of 53.68% is expected in the next year compared to the current price of 4.115. Check the CUREVAC NV stock analysts ratings, price target forecast and up-and down grades for more detailed information.
CUREVAC NV (CVAC) has a market capitalization of 926.53M USD. This makes CVAC a Small Cap stock.
CUREVAC NV (CVAC) currently has 904 employees.
CUREVAC NV (CVAC) has a support level at 3.59 and a resistance level at 4.22. Check the full technical report for a detailed analysis of CVAC support and resistance levels.
The Revenue of CUREVAC NV (CVAC) is expected to decline by -84.72% in the next year. Check the estimates tab for more information on the CVAC EPS, Sales, EBIT and EBITDA future analyst estimates.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
CVAC does not pay a dividend.
CUREVAC NV (CVAC) will report earnings on 2025-08-13.
The PE ratio for CUREVAC NV (CVAC) is 4.47. This is based on the reported non-GAAP earnings per share of 0.92 and the current share price of 4.115 USD. Check the full fundamental report for a full analysis of the valuation metrics for CVAC.
The outstanding short interest for CUREVAC NV (CVAC) is 5.2% of its float. Check the ownership tab for more information on the CVAC short interest.
ChartMill assigns a technical rating of 9 / 10 to CVAC. When comparing the yearly performance of all stocks, CVAC is one of the better performing stocks in the market, outperforming 89.16% of all stocks.
ChartMill assigns a fundamental rating of 6 / 10 to CVAC. CVAC is in great health and has no worries on liquidiy or solvency at all, but the profibility rating is only average.
Over the last trailing twelve months CVAC reported a non-GAAP Earnings per Share(EPS) of 0.92. The EPS increased by 166.39% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | 30.3% | ||
ROA | 20.2% | ||
ROE | 23.28% | ||
Debt/Equity | 0.05 |
ChartMill assigns a Buy % Consensus number of 78% to CVAC. The Buy consensus is the average rating of analysts ratings from 13 analysts.
For the next year, analysts expect an EPS growth of -172.19% and a revenue growth -84.72% for CVAC